PZ0193
阿西替尼
≥98% (HPLC), powder, tyrosine kinase inhibitor
别名:
AG-013736, N-甲基-2-((3-((1E)-2-(吡啶-2-基)乙烯)-1H-吲唑-6-基)硫)苯甲酰胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H18N4OS
化学文摘社编号:
分子量:
386.47
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
阿西替尼, ≥98% (HPLC)
SMILES string
CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2
InChI key
RITAVMQDGBJQJZ-FMIVXFBMSA-N
InChI
1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
assay
≥98% (HPLC)
form
powder
color
white to tan
solubility
DMSO: ≥8 mg/mL
storage temp.
room temp
Quality Level
Gene Information
human ... FLT1(2321), FLT4(2324), KDR(3791)
Application
阿昔替尼已被用作血管内皮生长因子 (VEGF) 受体酪氨酸激酶抑制剂 (TKI) ，以研究其对肾癌细胞体外增殖的影响。此外，在调理水 (CW) 中维持的脱氯胚胎中，它还用于抑制肠系膜上动脉 (AMA) 血管生成。
Biochem/physiol Actions
口服有效的选择性 VEGF 受体1、2和3抑制剂
阿昔替尼 (AG-013736) 是一种口服强效（皮摩）选择性酪氨酸激酶抑制剂，可阻断VEGF受体 1、2 和 3。该药物可通过内皮型一氧化氮合成酶、Akt和细胞外信号调节激酶，阻断VEGF介导的内皮细胞存活、血管形成及下游信号传导。
Features and Benefits
这种化合物是激酶磷酸酶生物学研究的特色产品。点击此处发现更多特色激酶磷酸酶生物产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells
Bielecka Z, et al.
Cell & Bioscience, 7(1), 71-71 (2017)
Renin expression in developing zebrafish is associated with angiogenesis and requires the Notch pathway and endothelium
Rider S, et al.
American Journal of Physiology: Renal Physiology, 309(6), F531-F539 (2015)
Fatma Demircan Yildirim et al.
Medycyna pracy, 71(6), 649-663 (2020-10-28)
About 8 million healthcare workers in the USA are potentially exposed to hazardous drugs or their toxic metabolites over a long period of time despite the fact that both the Occupational Safety and Health Administration and the European Parliament recommend
Akira Kazama et al.
Oncology reports, 46(4) (2021-09-02)
The selection of effective therapeutic agents is critical for improving the survival of patients with renal cell carcinoma (RCC). The aim of the present study was to develop an ex vivo drug testing assay using patient‑derived tumor organoid (TO) cultures. For this purpose
Heidi I Chen et al.
The Journal of clinical investigation, 124(11), 4899-4914 (2014-10-02)
Coronary arteries (CAs) stem from the aorta at 2 highly stereotyped locations, deviations from which can cause myocardial ischemia and death. CA stems form during embryogenesis when peritruncal blood vessels encircle the cardiac outflow tract and invade the aorta, but
商品
Discover Bioactive Small Molecules for Kinase Phosphatase Biology
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持